AU2007316137A1 - DMAE as sole agent for the treatment of mild cognitive impairment - Google Patents
DMAE as sole agent for the treatment of mild cognitive impairment Download PDFInfo
- Publication number
- AU2007316137A1 AU2007316137A1 AU2007316137A AU2007316137A AU2007316137A1 AU 2007316137 A1 AU2007316137 A1 AU 2007316137A1 AU 2007316137 A AU2007316137 A AU 2007316137A AU 2007316137 A AU2007316137 A AU 2007316137A AU 2007316137 A1 AU2007316137 A1 AU 2007316137A1
- Authority
- AU
- Australia
- Prior art keywords
- dmae
- use according
- dimethylaminoethanol
- medicinal product
- allowing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000010877 cognitive disease Diseases 0.000 title claims description 39
- 208000027061 mild cognitive impairment Diseases 0.000 title claims description 29
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 title claims description 25
- 238000011282 treatment Methods 0.000 title claims description 11
- 206010012289 Dementia Diseases 0.000 claims description 16
- 230000003109 amnesic effect Effects 0.000 claims description 14
- 229960002887 deanol Drugs 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 8
- 229940126601 medicinal product Drugs 0.000 claims description 7
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 6
- 230000000971 hippocampal effect Effects 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 4
- 229940043131 pyroglutamate Drugs 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- 229940049953 phenylacetate Drugs 0.000 claims description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- PXKVCJOCQWPPDT-MLWJPKLSSA-N 1-(dimethylamino)ethyl (2S)-5-oxopyrrolidine-2-carboxylate Chemical compound N1[C@@H](CCC1=O)C(=O)OC(C)N(C)C PXKVCJOCQWPPDT-MLWJPKLSSA-N 0.000 claims 1
- DAEHWWVKPWBXGD-DFWYDOINSA-N 2-(dimethylamino)ethanol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound CN(C)CCO.OC(=O)[C@@H]1CCC(=O)N1 DAEHWWVKPWBXGD-DFWYDOINSA-N 0.000 claims 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 15
- 230000001149 cognitive effect Effects 0.000 description 11
- 230000015654 memory Effects 0.000 description 11
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000006735 deficit Effects 0.000 description 6
- 206010027175 memory impairment Diseases 0.000 description 6
- 208000026139 Memory disease Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000006999 cognitive decline Effects 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000036626 alertness Effects 0.000 description 3
- 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 230000007000 age related cognitive decline Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229940055075 anticholinesterase parasympathomimetics Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galantamine Natural products O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 1
- 244000050907 Hedychium coronarium Species 0.000 description 1
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000007334 memory performance Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0609548 | 2006-10-31 | ||
| FR0609548A FR2907679B1 (fr) | 2006-10-31 | 2006-10-31 | Utilisation de dmae pour le traitement de deficit cognitif leger |
| PCT/EP2007/061737 WO2008053011A1 (fr) | 2006-10-31 | 2007-10-31 | Le dmae en tant qu'agent unique pour le traitement de deficit cognitif leger |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2007316137A1 true AU2007316137A1 (en) | 2008-05-08 |
Family
ID=38050144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007316137A Abandoned AU2007316137A1 (en) | 2006-10-31 | 2007-10-31 | DMAE as sole agent for the treatment of mild cognitive impairment |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8207218B2 (enExample) |
| EP (1) | EP2083814B1 (enExample) |
| JP (1) | JP2010508253A (enExample) |
| KR (1) | KR20090082428A (enExample) |
| CN (1) | CN101528220A (enExample) |
| AR (1) | AR063764A1 (enExample) |
| AU (1) | AU2007316137A1 (enExample) |
| BR (1) | BRPI0718263A2 (enExample) |
| CA (1) | CA2667983A1 (enExample) |
| FR (1) | FR2907679B1 (enExample) |
| IL (1) | IL198463A0 (enExample) |
| MA (1) | MA30925B1 (enExample) |
| MX (1) | MX2009004682A (enExample) |
| NO (1) | NO20092099L (enExample) |
| RU (1) | RU2009120137A (enExample) |
| TN (1) | TN2009000159A1 (enExample) |
| WO (1) | WO2008053011A1 (enExample) |
| ZA (1) | ZA200903626B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150157046A1 (en) * | 2013-12-10 | 2015-06-11 | Lifewave, Inc. | Nutritional product composition for the mind |
| EP4736750A3 (en) * | 2022-05-02 | 2026-07-15 | Emocog Co., Ltd. | Test method and apparatus for evaluating cognitive function decline |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003003981A2 (en) * | 2001-07-05 | 2003-01-16 | Vital Basics, Inc. | Compositions for improving mental performance |
| US20060211721A1 (en) * | 2005-03-21 | 2006-09-21 | Roberts Alan R | Nutraceutical formulation of a cognitive enhancement system |
-
2006
- 2006-10-31 FR FR0609548A patent/FR2907679B1/fr not_active Expired - Fee Related
-
2007
- 2007-10-31 CA CA002667983A patent/CA2667983A1/fr not_active Abandoned
- 2007-10-31 KR KR1020097010586A patent/KR20090082428A/ko not_active Withdrawn
- 2007-10-31 WO PCT/EP2007/061737 patent/WO2008053011A1/fr not_active Ceased
- 2007-10-31 JP JP2009533884A patent/JP2010508253A/ja not_active Withdrawn
- 2007-10-31 AR ARP070104851A patent/AR063764A1/es not_active Application Discontinuation
- 2007-10-31 MX MX2009004682A patent/MX2009004682A/es not_active Application Discontinuation
- 2007-10-31 EP EP07822084A patent/EP2083814B1/fr active Active
- 2007-10-31 RU RU2009120137/15A patent/RU2009120137A/ru not_active Application Discontinuation
- 2007-10-31 BR BRPI0718263-5A patent/BRPI0718263A2/pt not_active IP Right Cessation
- 2007-10-31 US US12/447,816 patent/US8207218B2/en not_active Expired - Fee Related
- 2007-10-31 CN CNA2007800401804A patent/CN101528220A/zh active Pending
- 2007-10-31 AU AU2007316137A patent/AU2007316137A1/en not_active Abandoned
-
2009
- 2009-04-24 TN TNP2009000159A patent/TN2009000159A1/fr unknown
- 2009-04-30 IL IL198463A patent/IL198463A0/en unknown
- 2009-05-26 ZA ZA200903626A patent/ZA200903626B/xx unknown
- 2009-05-27 MA MA31926A patent/MA30925B1/fr unknown
- 2009-05-28 NO NO20092099A patent/NO20092099L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TN2009000159A1 (fr) | 2010-10-18 |
| BRPI0718263A2 (pt) | 2014-01-07 |
| ZA200903626B (en) | 2010-07-28 |
| MA30925B1 (fr) | 2009-11-02 |
| FR2907679A1 (fr) | 2008-05-02 |
| US8207218B2 (en) | 2012-06-26 |
| WO2008053011A1 (fr) | 2008-05-08 |
| RU2009120137A (ru) | 2010-12-10 |
| US20090298908A1 (en) | 2009-12-03 |
| EP2083814A1 (fr) | 2009-08-05 |
| IL198463A0 (en) | 2010-02-17 |
| CA2667983A1 (fr) | 2008-05-08 |
| AR063764A1 (es) | 2009-02-18 |
| FR2907679B1 (fr) | 2009-10-30 |
| EP2083814B1 (fr) | 2013-03-20 |
| JP2010508253A (ja) | 2010-03-18 |
| NO20092099L (no) | 2009-07-17 |
| MX2009004682A (es) | 2009-09-28 |
| KR20090082428A (ko) | 2009-07-30 |
| CN101528220A (zh) | 2009-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Forette et al. | A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®) | |
| Jann | Rivastigmine, a new‐generation cholinesterase inhibitor for the treatment of Alzheimer's disease | |
| Agid et al. | Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type | |
| Raskind et al. | The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients | |
| Bartorelli et al. | Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease | |
| US20070281010A1 (en) | Compositions And Methods For Enhancing Brain Function | |
| US9737519B2 (en) | Compositions and methods for enhancing brain function | |
| Gorman et al. | Cholinergic therapy of behavioral disturbances in Alzheimer's disease | |
| Weinstock | Possible role of the cholinergic system and disease models | |
| Marin et al. | L-deprenyl and physostigmine for the treatment of Alzheimer's disease | |
| US8207218B2 (en) | DMAE as sole agent for the treatment of mild cognitive impairment | |
| JPH1045582A (ja) | アルツハイマー病の早期発病患者を治療するためのカルニチン誘導体を含む医薬 | |
| Reisberg et al. | Piracetam in the treatment of cognitive impairment in the elderly | |
| Grossberg | Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease | |
| Herrmann | Cognitive pharmacotherapy of Alzheimer's disease and other dementias | |
| TW202038955A (zh) | 用於治療多巴胺性cns病症之ly3154207劑量療法 | |
| US5747494A (en) | Pharmaceutical compositions for the treatment of depressive disorders | |
| HK1135909A (en) | Dmae as sole agent for the treatment of mild cognitive impairment | |
| Thal | Physostigmine in Alzheimer’s disease | |
| Sim | Rivastigmine: a review | |
| Hamidia et al. | A Comparative Study of the Efficacy of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder | |
| Kase | Subcortical hemorrhages | |
| Sethi et al. | Tricyclic anti-depressant induced mania | |
| JP2007532624A (ja) | アルツハイマー病の治療のための療法組合せ | |
| Cutler et al. | P-8-10 Safety and tolerance of ENA 713 in Alzheimer's disease (AD) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |